Australian GPs are increasingly entering consultations that have already started without them. Patients arrive with self-researched diagnoses, treatment preferences, and safety concerns sourced from Google, AI tools, and social media.
For pharma, this shift redefines the engagement opportunity: it’s no longer just about building product awareness with doctors. It’s about equipping them to have better conversations with patients who are already informed and often misinformed.
The consultation has already started before the patient arrives
Traditionally, the GP was the primary and, in many cases, the only source of health information. However today, GPs are often entering a conversation that has started without them.
Through access to Google and now fast developing AI tools, patients may arrive with:
- A suspected diagnosis
- A preferred treatment option
- Concerns about safety or side effects of prescribed medications
- Information gathered from multiple sources, some more credible than others
This does not diminish the role of clinical expertise, instead it highlights a new reality: the decision-making environment around the patient has become much broader and more demanding.
GPs are no longer just translating evidence into care decisions; they are also helping patients understand which information can be trusted.
Why is trust now harder to build in the healthcare information environment?
The challenge facing healthcare is not a lack of information, it’s knowing what information to trust.
This is particularly relevant as patients increasingly engage with health information sources outside traditional and potentially more rigorous clinical channels.
For GPs, the ability to separate this evidence from potentially harmful noise has now become a core part of the consultation.
The opportunity for pharma is not more messaging, but a focus on quality and access
In a world where patients are already exposed to more health information than ever before, adding more messages is unlikely to solve the challenge. The opportunity is to help doctors navigate these patient conversations with confidence.
GPs consistently highlight the value of evidence-led, practical support. These insights highlight an important distinction.
Doctors are not looking for more promotional content; they are looking for information that improves clinical conversations.
As one doctor noted:
“Give me succinct information that helps in my everyday role.” GP respondent, AusDoc BIG Doctor Survey 2025
How should pharma shift from product awareness to supporting patient conversations?
Historically, pharmaceutical engagement has focused on ensuring doctors are aware of new products.
As one GP noted, “Education materials and sessions … keep me aware of what’s coming to market.” GP respondent, AusDoc BIG Doctor Survey 2025
But as patient behaviours increasingly influence consultations, the opportunity is clearer. How can pharma help doctors have better conversations with patients? This means supporting areas such as:
- Clear explanations of treatment options
- Balanced patient education resources
- Better understanding of emerging therapies
- Evidence that helps address common questions and concerns
As one GP described the value of effective industry support: “The rep helped me choose a safer and more effective option for a complex diabetic.” GP respondent, AusDoc BIG Doctor Survey 20257
The value was not the product discussion alone. It was the ability to support a better patient outcome.
The practical question is how pharma delivers that support at scale and consistently, not just when a rep is in the room.
GPs consistently highlight the value of evidence-led, practical support that helps them address patient questions with confidence. That means:
- Clear, concise treatment summaries doctors can reference quickly between patients, not long-form promotional content
- Balanced patient education resources GPs can share directly in the consultation or recommend after it
- Clinical education that addresses the specific questions patients are bringing in
- Evidence presented through trusted, independent platforms doctors already use, not through company microsites that require separate logins and add friction
AusDoc’s promoted content, CPD modules, and eNewsletter advertorials are specifically built for this model: clinical information delivered in the trusted editorial environment doctors already rely on, at the moment they’re ready to engage.
What does the new GP decision-making landscape mean for pharma engagement?
The future of healthcare communication will not be defined by reach alone. It will be defined by how effectively pharma understands and supports the environment in which prescribing decisions are made.
Patients will continue to arrive informed, influenced, and often uncertain.
Doctors will continue to interpret evidence within the context of those expectations.
Pharma’s role is evolving beyond awareness-building.
It is about enabling better conversations, equipping doctors with the clarity, confidence, and evidence needed to navigate increasingly informed patient interactions and deliver better outcomes.
Because increasingly, the most important moment in healthcare does not begin when the GP opens the patient’s record. It begins with everything that happened before.
FAQs
How is patient pre-consultation research changing the GP’s role?
GPs increasingly spend consultation time navigating patient-sourced information — self-diagnoses from Google, AI-generated health summaries, treatment preferences from social media, and safety concerns from online forums. Clinical expertise now includes helping patients evaluate what information can be trusted.
What do Australian GPs want from pharma to support patient consultations?
GPs consistently value concise, evidence-led information that helps them address patient questions with confidence. They want practical clinical support clear treatment summaries, balanced patient education resources, and evidence that helps navigate common patient concerns, not additional promotional messaging.
Why is more pharma messaging not the solution?
Australian doctors already report being overwhelmed by digital pharma communication. AusDoc’s 2024 survey found 55% want less digital communication from pharma and 60% say promotional product content is what overwhelms them most. The opportunity is quality and relevance, not volume.
How can pharma help GPs navigate the informed patient challenge?
The most effective approach is providing evidence-led content that helps GPs explain treatment options clearly, address patient concerns confidently, and make evidence-based decisions quickly.
This content performs best when delivered through trusted, independent platforms doctors already use — not through company-owned channels that trigger scepticism before a word is read.
How does AusDoc support pharma brands in this environment?
AusDoc gives pharma brands a trusted, editorially independent channel to reach 62,000 AHPRA-verified Australian doctors with clinical education, promoted content, and evidence summaries in the platform doctors already rely on for independent medical news and CPD.
Explore our solutions → here
Help Australian GPs have better patient conversations
AusDoc connects pharma brands with 62,000 AHPRA-verified Australian doctors through trusted, independent clinical content, delivered in the platform they already use, at the moment they’re ready to engage.
Alternatively explore our solutions.
Sources:
AusDoc BIG Doctor Survey, September 2025 (n=1,430)
AusDoc Survey, “Doctor Understanding and Use of Digital Health Solutions,” February 2025 (n=162)
AusDoc Survey, “Understanding doctor insights and behaviours with the use of weight-loss medications,” May 2024 (n=391)
AusDoc Inside Healthcare: Rebuilding Trust: The Strategic Imperative Pharma Can No Longer Ignore
AusDoc Inside Healthcare: How do busy GPs want to find out about new medications?